Apollo Endosurgery (NASDAQ:APEN) Director Matthew S. Crawford Buys 4,038 Shares

Apollo Endosurgery (NASDAQ:APEN) Director Matthew S. Crawford purchased 4,038 shares of the stock in a transaction that occurred on Friday, March 9th. The shares were purchased at an average cost of $6.20 per share, for a total transaction of $25,035.60. Following the completion of the acquisition, the director now directly owns 53,715 shares of the company’s stock, valued at approximately $333,033. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

APEN stock traded down $0.01 during mid-day trading on Friday, hitting $6.00. 12,505 shares of the company were exchanged, compared to its average volume of 27,348. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.23 and a quick ratio of 1.68. The firm has a market cap of $103.92, a PE ratio of -2.99 and a beta of 0.34. Apollo Endosurgery has a 12-month low of $3.55 and a 12-month high of $13.48.

How to Become a New Pot Stock Millionaire

Apollo Endosurgery (NASDAQ:APEN) last announced its earnings results on Thursday, March 1st. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.08). Apollo Endosurgery had a negative return on equity of 64.48% and a negative net margin of 42.35%. The company had revenue of $16.14 million for the quarter, compared to analysts’ expectations of $16.64 million. sell-side analysts anticipate that Apollo Endosurgery will post -1.44 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of APEN. Stonepine Capital Management LLC purchased a new position in Apollo Endosurgery in the third quarter worth approximately $11,067,000. King Luther Capital Management Corp purchased a new position in Apollo Endosurgery in the third quarter worth approximately $2,567,000. Russell Investments Group Ltd. purchased a new position in Apollo Endosurgery in the third quarter worth approximately $1,288,000. Woodmont Investment Counsel LLC purchased a new position in Apollo Endosurgery in the third quarter worth approximately $220,000. Finally, JPMorgan Chase & Co. purchased a new position in Apollo Endosurgery in the third quarter worth approximately $119,000. Institutional investors own 31.27% of the company’s stock.

Several research firms have issued reports on APEN. Zacks Investment Research downgraded shares of Apollo Endosurgery from a “hold” rating to a “sell” rating in a report on Tuesday, March 6th. Northland Securities reiterated a “buy” rating and issued a $12.00 target price on shares of Apollo Endosurgery in a research report on Thursday, February 8th. ValuEngine upgraded shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, Roth Capital set a $10.00 target price on shares of Apollo Endosurgery and gave the company a “buy” rating in a research report on Thursday, January 4th. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $9.44.

ILLEGAL ACTIVITY WARNING: “Apollo Endosurgery (NASDAQ:APEN) Director Matthew S. Crawford Buys 4,038 Shares” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/insider-buying-apollo-endosurgery-inc-apen-director-buys-25035-60-in-stock.html.

Apollo Endosurgery Company Profile

Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply